Stock Evaluator: QuidelOrtho Corporation (QDEL)

QuidelOrtho Corporation QDEL

$16.77 0.20 1.21%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 739,523
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics QDEL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,127.9 $334.8 46%
Shares Out (Mil) 68.2 41.7 55%
Institutional Ownership 99.1% 77.3% 85%
Float (Mil) 62.1 34.7 52%
Beta 0.76 0.86 44%
Avg Daily Volume (000s) 1,045 266 72%
Price Change
(52-week)
(35.0%) 60.7% 22%
Growth QDEL Industry
Median
Percentile
(All Stocks)
Sales (5yr) 10.4% 11.8% 60%
Net Income (5yr) (27.7%) (5.8%) 15%
EPS (5yr) (23.7%) 10.7% 11
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (36.8%) (16.1%) 13%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.047) $1.842 $2.390
Month Ago EPS $0.019 $1.919 $2.545
# Rev Up 0 1 0
# Rev Down 1 1 1
Three Months Ago EPS $0.107 $2.147 $2.866
Year/Year Chg (96.5%) (111.0%) (116.8%)
Financials QDEL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $2,657 $152 65%
Net Income (TTM) (Mil) ($1,211) ($11) 1%
EPS (TTM) ($17.814) ($0.500) 3%
Operating Cash Flow (TTM) (Mil) $7 ($2) 37%
Net Cash Flow (TTM) (Mil) $13 $1 60%
Long-Term Debt (Q1) (Mil) $2,615 $22 78%
Enterprise Value (Q1) (Mil) $3,667 $304 58%
Valuation QDEL Industry
Median
Percentile
(All Stocks)
P/B 0.61 2.88 11%
P/E na 30.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.9 na
Ratios QDEL Industry
Median
Percentile
(All Stocks)
Gross Margin 45.2% 59.1% 57%
Net Margin (45.6%) (7.7%) 12%
ROA (20.0%) (13.7%) 21%
ROE (49.9%) (15.9%) 15%
Liabilities to Assets 67.1% 44.9% 62%
F-Score 4 4 34%

QuidelOrtho Corporation did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors